Deploying liquid intelligence in cancer: Finding answers in our blood.

Multimodal foundation models applied to liquid biopsy data could improve sensitivity for tumor-derived signals in blood despite sparse, heterogeneous biomarkers shaped by genetics and comorbidities.

• Why it matters: Liquid biopsies are noninvasive and scalable, but circulating tumor signals are often weak and confounded, limiting reliable cancer detection and monitoring.
• What they did: The review synthesizes liquid biopsy technologies and AI advances, focusing on multimodal foundation model pretraining on large cohorts and integration of complementary biomolecule modalities.
• The result: Converging liquid biopsy and multimodal AI is positioned to enhance cancer monitoring by better extracting tumor signals from noisy, high-dimensional blood measurements, while noting remaining clinical and infrastructural barriers.

AI summary of the abstract · may contain errors · not medical advice · read the paper.